Samia Menif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samia Menif has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Foued Maaoui
Laboratory of Molecular and Cellular Hematology, Pasteur Institute of Tunis, Tunis, Tunisia
2 shared publications - Imen Moumni
Laboratory of Molecular and Cellular Hematology LR21IPT07, Pasteur Institute of Tunis, Tunis 1002, Tunisia
2 shared publications - Ines Safra
Laboratory of Molecular and Cellular Hematology, Pasteur Institute of Tunis, Tunis, Tunisia
2 shared publications - France Arboix-Calas
Faculty of Education, Montpellier University , Montpellier, Occitanie
1 shared publication - Hichem Ben Jannet
Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11Es39), Medicinal Chemistry and Natural Products, Faculty of Sciences of Monastir, University of Monastir, Avenue of Environment, Monastir 5000, Tunisia
1 shared publication - Imen Aissa
Team Medicinal Chemistry and Natural Products (LR11ES39), Laboratory of Heterocyclic, Chemistry, Natural Products and Reactivity, Department of Chemistry, Faculty of Science of Monastir, University of Monastir, Monastir 5019, Tunisia
1 shared publication
Latest Publications
- 2 June 2025
- Published by Elsevier in Journal of Cancer Policy
- Vol. 45, 100606
Integrating cancer education into Tunisian school curricula: A public health necessity
- 2 June 2025
- Published by Elsevier in Journal of Cancer Policy
- Vol. 45, 100606
Integrating cancer education into Tunisian school curricula: A public health necessity
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1)
Artificial intelligence and the challenge of genetic essentialism: interview with artificial intelligences on sickle-cell disease
Objectives: Sickle cell disease (SCD) has historically been associated with populations of African, Mediterranean, Middle Eastern, and Indian descent, often reinforcing genetic essentialism, a deterministic view of genetic inheritance. This study examines how artificial intelligence (AI) models address genetic essentialism in the context of SCD and assesses their potential influence on youth understanding of genetic risk. Methods: We conducted semi-structured interviews with three publicly available AI models: ChatGPT-3.5, DeepSeek-V3, and Qwen 2.5-Max. The models were asked five questions regarding SCD definition, hereditary risk estimation, risk assessment for a hypothetical couple, and premarital screening recommendations. Responses were analyzed qualitatively to identify patterns of genetic essentialism, biases, and epistemological simplifications. Results: AI models provided scientifically accurate but epidemiologically biased responses. They strongly linked SCD prevalence to ethnicity and geographic origin, reinforcing deterministic narratives. While they acknowledged genetic counseling and environmental factors, their explanations emphasized ancestry as the primary determinant of genetic risk. Moreover, the AI models exhibited a structured response pattern. While the response is scholarly and nuanced, it suggests that an individual’s likelihood of passing on the disease is chiefly determined by their genetic nationality. Conclusion: AI-generated health information, while grounded in biomedical knowledge, may inadvertently perpetuate genetic essentialism by emphasizing ethnicity-based risk factors. This has implications for genetic literacy, particularly among young users with limited critical engagement with AI-generated content. Addressing these biases requires the integration of digital health literacy, genetic literacy, and health literacy into educational frameworks to foster a nuanced understanding of genetic risk and disease prevention.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1)
Open AccessArtificial intelligence and the challenge of genetic essentialism: interview with artificial intelligences on sickle-cell disease
Objectives: Sickle cell disease (SCD) has historically been associated with populations of African, Mediterranean, Middle Eastern, and Indian descent, often reinforcing genetic essentialism, a deterministic view of genetic inheritance. This study examines how artificial intelligence (AI) models address genetic essentialism in the context of SCD and assesses their potential influence on youth understanding of genetic risk. Methods: We conducted semi-structured interviews with three publicly available AI models: ChatGPT-3.5, DeepSeek-V3, and Qwen 2.5-Max. The models were asked five questions regarding SCD definition, hereditary risk estimation, risk assessment for a hypothetical couple, and premarital screening recommendations. Responses were analyzed qualitatively to identify patterns of genetic essentialism, biases, and epistemological simplifications. Results: AI models provided scientifically accurate but epidemiologically biased responses. They strongly linked SCD prevalence to ethnicity and geographic origin, reinforcing deterministic narratives. While they acknowledged genetic counseling and environmental factors, their explanations emphasized ancestry as the primary determinant of genetic risk. Moreover, the AI models exhibited a structured response pattern. While the response is scholarly and nuanced, it suggests that an individual’s likelihood of passing on the disease is chiefly determined by their genetic nationality. Conclusion: AI-generated health information, while grounded in biomedical knowledge, may inadvertently perpetuate genetic essentialism by emphasizing ethnicity-based risk factors. This has implications for genetic literacy, particularly among young users with limited critical engagement with AI-generated content. Addressing these biases requires the integration of digital health literacy, genetic literacy, and health literacy into educational frameworks to foster a nuanced understanding of genetic risk and disease prevention.
- Open Access
Tyrosol Derivatives, Bearing 3,5-Disubstituted Isoxazole and 1,4-Disubstituted Triazole, as Potential Antileukemia Agents by Promoting Apoptosis
In the present study, we assess tyrosol derivatives bearing 3,5-disubstituted isoxazoles and 1,4-disubstituted triazoles for their ability to inhibit the proliferation of K562 cells derived from leukemia as well as primary chronic myeloid leukemia (CML) cells obtained from the peripheral blood of 15 CML patients including 10 patients with untreated chronic phase and 5 patients with resistance against imatinib or multiple TKI. Our results showed that most derivatives displayed significant anti-proliferative activity against K562 cells in a dose-dependent manner. Among them, compounds 3d and 4a exhibited greater potent anticancer activity with respective IC50 values of 16 and 18 µg/mL (45 µM and 61 µM). Interestingly, compound 3d inhibited CML cell proliferation not only in newly diagnosed but also in imatinib-resistant patients. We demonstrated that the anti-proliferative effect of this compound is mediated by a pro-apoptotic activity by promoting oxidative stress and modulating the activity of the Akt, p38 MAPK and Erk 1/2 pathways. In conclusion, our data highlight the potential of this class of derivative as a novel promising therapeutic agent for CML therapy.
Open AccessTyrosol Derivatives, Bearing 3,5-Disubstituted Isoxazole and 1,4-Disubstituted Triazole, as Potential Antileukemia Agents by Promoting Apoptosis
In the present study, we assess tyrosol derivatives bearing 3,5-disubstituted isoxazoles and 1,4-disubstituted triazoles for their ability to inhibit the proliferation of K562 cells derived from leukemia as well as primary chronic myeloid leukemia (CML) cells obtained from the peripheral blood of 15 CML patients including 10 patients with untreated chronic phase and 5 patients with resistance against imatinib or multiple TKI. Our results showed that most derivatives displayed significant anti-proliferative activity against K562 cells in a dose-dependent manner. Among them, compounds 3d and 4a exhibited greater potent anticancer activity with respective IC50 values of 16 and 18 µg/mL (45 µM and 61 µM). Interestingly, compound 3d inhibited CML cell proliferation not only in newly diagnosed but also in imatinib-resistant patients. We demonstrated that the anti-proliferative effect of this compound is mediated by a pro-apoptotic activity by promoting oxidative stress and modulating the activity of the Akt, p38 MAPK and Erk 1/2 pathways. In conclusion, our data highlight the potential of this class of derivative as a novel promising therapeutic agent for CML therapy.